PubMed:19707748 / 828-1000 JSONTXT

{"project":"Inflammaging","denotations":[{"id":"T12","span":{"begin":0,"end":172},"obj":"Sentence"},{"id":"T12","span":{"begin":0,"end":172},"obj":"Sentence"}],"text":"Clinicians are exhorted to pay close attention when initiating levofloxacin therapy in patients taking medications with epileptogenic properties that are CYP1A2 substrates."}

{"project":"LitCoin-sentences","denotations":[{"id":"T12","span":{"begin":0,"end":172},"obj":"Sentence"}],"text":"Clinicians are exhorted to pay close attention when initiating levofloxacin therapy in patients taking medications with epileptogenic properties that are CYP1A2 substrates."}

{"project":"LitCoin-entities","denotations":[{"id":"6411","span":{"begin":63,"end":75},"obj":"ChemicalEntity"},{"id":"6412","span":{"begin":87,"end":95},"obj":"OrganismTaxon"},{"id":"6413","span":{"begin":154,"end":160},"obj":"GeneOrGeneProduct"}],"attributes":[{"id":"A14","pred":"db_id","subj":"6411","obj":"MESH:D064704"},{"id":"A15","pred":"db_id","subj":"6412","obj":"NCBITaxon:9606"},{"id":"A16","pred":"db_id","subj":"6413","obj":"NCBIGene:1544"}],"namespaces":[{"prefix":"_base","uri":"https://w3id.org/biolink/vocab/"},{"prefix":"MESH","uri":"http://id.nlm.nih.gov/mesh/"},{"prefix":"NCBITaxon","uri":"https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id="},{"prefix":"NCBIGene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"OMIM","uri":"https://www.omim.org/entry/"},{"prefix":"DBSNP","uri":"https://www.ncbi.nlm.nih.gov/snp/"}],"text":"Clinicians are exhorted to pay close attention when initiating levofloxacin therapy in patients taking medications with epileptogenic properties that are CYP1A2 substrates."}

{"project":"LitCoin-GeneOrGeneProduct-v0","denotations":[{"id":"T25","span":{"begin":52,"end":62},"obj":"GeneOrGeneProduct"},{"id":"T26","span":{"begin":154,"end":160},"obj":"GeneOrGeneProduct"}],"text":"Clinicians are exhorted to pay close attention when initiating levofloxacin therapy in patients taking medications with epileptogenic properties that are CYP1A2 substrates."}

{"project":"LitCoin-GeneOrGeneProduct-v2","denotations":[{"id":"T10","span":{"begin":154,"end":160},"obj":"GeneOrGeneProduct"}],"text":"Clinicians are exhorted to pay close attention when initiating levofloxacin therapy in patients taking medications with epileptogenic properties that are CYP1A2 substrates."}

{"project":"LitCoin-GeneOrGeneProduct-v3","denotations":[{"id":"T3","span":{"begin":154,"end":160},"obj":"GeneOrGeneProduct"}],"text":"Clinicians are exhorted to pay close attention when initiating levofloxacin therapy in patients taking medications with epileptogenic properties that are CYP1A2 substrates."}

{"project":"LitCoin-Chemical-MeSH-CHEBI","denotations":[{"id":"T15","span":{"begin":63,"end":75},"obj":"ChemicalEntity"}],"attributes":[{"id":"A15","pred":"ID:","subj":"T15","obj":"D064704"},{"id":"A16","pred":"ID:","subj":"T15","obj":"http://purl.obolibrary.org/obo/CHEBI_63598"}],"text":"Clinicians are exhorted to pay close attention when initiating levofloxacin therapy in patients taking medications with epileptogenic properties that are CYP1A2 substrates."}

{"project":"LitCoin-NCBITaxon-2","denotations":[{"id":"T2","span":{"begin":87,"end":95},"obj":"OrganismTaxon"}],"text":"Clinicians are exhorted to pay close attention when initiating levofloxacin therapy in patients taking medications with epileptogenic properties that are CYP1A2 substrates."}

{"project":"LitCoin-training-merged","denotations":[{"id":"T15","span":{"begin":63,"end":75},"obj":"ChemicalEntity"},{"id":"T98723","span":{"begin":154,"end":160},"obj":"GeneOrGeneProduct"},{"id":"T84749","span":{"begin":87,"end":95},"obj":"OrganismTaxon"}],"attributes":[{"id":"A16","pred":"ID:","subj":"T15","obj":"http://purl.obolibrary.org/obo/CHEBI_63598"},{"id":"A15","pred":"ID:","subj":"T15","obj":"D064704"}],"text":"Clinicians are exhorted to pay close attention when initiating levofloxacin therapy in patients taking medications with epileptogenic properties that are CYP1A2 substrates."}